Stanbic IBTC alerts NGX to possible H1 filing delay

Stanbic IBTC Holdings Plc has informed the Nigerian Exchange Limited (NGX) and its stakeholders of a possible delay in submitting its Audited Financial Statements for the half-year period ending June 30, 2026. The financial holding company indicated that the submission might not meet the statutory deadline of August 28, 2026.

In a regulatory statement signed by Group Company Secretary Chidi Okezie, Stanbic IBTC explained that it is currently in the final stages of auditing its half-year results. Following the completion of the audit, the company will need to obtain necessary approvals from its primary regulator, the Central Bank of Nigeria (CBN), before releasing the financial scorecard to the public.

The company assured shareholders and the market that all efforts are being made to expedite the process. Stanbic IBTC aims to publish its 2026 Audited Half Year Financial Statements around or shortly after the regulatory due date, once all required approvals are secured. This notification is in line with NGX post-listing rules, which require companies to submit interim reports within specific timeframes, with provisions for regulatory clearance for financial institutions.

Under NGX rules, quoted companies typically have 30 to 60 days after the end of a period to submit quarterly and half-year reports. However, commercial banks and financial holding institutions often require formal clearance from the CBN, which can extend review timelines beyond standard submission dates. Stanbic IBTC's announcement follows this established procedure for entities subject to central bank oversight.

“

This is to inform Nigerian Exchange Limited as well as our Esteemed Stakeholders that Stanbic IBTC Holdings Plc may experience a delay in filing its Audited Financial Statements for the Half Year ended 30 June 2026, by the due date of 28 August 2026. The company is currently finalising the audit of its 2026 Half Year Results, following which we would also be seeking the required regulatory approvals.